Valuation: Glaukos Corporation

Capitalization 6.25B 5.32B 4.97B 4.68B 8.62B 566B 9.41B 58.06B 22.52B 267B 23.45B 22.96B 974B P/E ratio 2025 *
-89.4x
P/E ratio 2026 * -177x
Enterprise value 6.02B 5.13B 4.79B 4.51B 8.3B 545B 9.06B 55.91B 21.69B 257B 22.58B 22.11B 938B EV / Sales 2025 *
12.2x
EV / Sales 2026 * 9.73x
Free-Float
96.76%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.32%
1 week+0.34%
Current month+2.44%
1 month+20.94%
3 months+31.56%
6 months+11.56%
Current year-27.38%
More quotes
1 week 105.88
Extreme 105.88
110.87
1 month 87.32
Extreme 87.3196
112
Current year 73.16
Extreme 73.16
163.71
1 year 73.16
Extreme 73.16
163.71
3 years 40.45
Extreme 40.45
163.71
5 years 33.33
Extreme 33.33
163.71
10 years 14.25
Extreme 14.25
163.71
More quotes
Manager TitleAgeSince
Chief Executive Officer 64 2000-12-31
Director of Finance/CFO 55 2022-03-31
President 49 2022-03-31
Director TitleAgeSince
Chairman 64 2021-12-30
Director/Board Member 70 2014-06-30
Director/Board Member 57 2014-06-30
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.32%+0.34%-21.63%+146.22% 6.25B
+0.32%-2.73%-5.48%+39.50% 135B
+0.08%-3.91%+21.77%+8.04% 13.79B
+0.04%-2.46%-33.91%-63.35% 5.96B
-4.87%-4.48%-30.43%-48.93% 3.8B
+0.75%-.--%-.--%+10.22% 3.63B
-2.34%-3.21%+46.83%+26.35% 2.69B
+3.97%+3.03%+1.64%-11.85% 2.33B
+1.17%-1.96%-21.53%-30.68% 1.57B
-4.85%-2.04%-42.63%-52.08% 1.51B
Average -0.60%-1.40%-8.54%+2.35% 17.69B
Weighted average by Cap. +0.14%-2.56%-4.87%+32.58%
See all sector performances

Financials

2025 *2026 *
Net sales 494M 421M 393M 370M 681M 44.72B 744M 4.59B 1.78B 21.08B 1.85B 1.81B 76.91B 613M 522M 487M 459M 844M 55.48B 922M 5.69B 2.21B 26.15B 2.3B 2.25B 95.42B
Net income -66.45M -56.6M -52.88M -49.75M -91.59M -6.02B -100M -617M -239M -2.84B -249M -244M -10.35B -34.48M -29.37M -27.44M -25.82M -47.53M -3.12B -51.92M -320M -124M -1.47B -129M -127M -5.37B
Net Debt -231M -197M -184M -173M -319M -20.96B -348M -2.15B -834M -9.88B -868M -850M -36.04B -291M -248M -231M -218M -401M -26.34B -438M -2.7B -1.05B -12.42B -1.09B -1.07B -45.3B
More financial data * Estimated data
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Employees
995
More about the company
Date Price Change Volume
25-12-12 108.88 $ -0.32% 477,183
25-12-11 109.23 $ +0.47% 787,728
25-12-10 108.72 $ +1.73% 1,023,785
25-12-09 106.87 $ -1.47% 737,959
25-12-08 108.46 $ -0.05% 642,434

Delayed Quote Nyse, December 12, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
108.88USD
Average target price
121.93USD
Spread / Average Target
+11.98%
Consensus

Quarterly revenue - Rate of surprise